Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011743 | 0.85 | MAOA (0.56) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL19512604 | 0.85 | MAOA (0.56) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL13460942 | 0.81 | CHRNB2 (0.39) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL18664431 | 0.81 | CHRNB2 (0.39) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL16057669 | 0.80 | KDM1A (0.50) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL21959060 | 0.80 | MAOA (0.64) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL6159366 | 0.80 | HTR2A (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL22680299 | 0.80 | MAOA (0.54) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL22680298 | 0.80 | MAOA (0.54) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL626535 | 0.80 | MAOA (0.54) | MAOADRD2TSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210380-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210375-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| WO-2011124093-A1 | BICYCLIC QUINOLONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-10-13 | — | — | WO | disclosed |
| EP-0677049-B1 | QUINAZOLINE DERIVATIVES | YUHAN CORP LTD (KR) | 2001-07-25 | — | — | EP | disclosed |
| US-5686458-A | Quinazoline deriviates for treating peptic ulcer | YUHAN CORPORATION (KR) | 1997-11-11 | — | — | US | disclosed |
| EP-0677049-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION, LTD. (KR) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014795-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION (KR) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | MAOA 2268/4885DRD2 2643/4885TSHR 449/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | MAOA 2268/4885DRD2 2643/4885TSHR 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.